Aims To evaluate whether stents as compared to balloon angioplasty reduce mortality in patients with non-acute coronary artery disease.
Introduction
Since the introduction of the first stents in 1987 1 their use in patients with coronary artery disease has steadily increased. Today over 1 million coronary angioplasty procedures are performed every year in the USA. 2 In Europe stents are used in more than 70% of these procedures. 3 Clinical trials have shown that stents reduce restenosis and revascularization compared to simple balloon angioplasty. [4] [5] [6] The introduction of sirolimus-and paclitaxel eluting stents is another breakthrough in the treatment of coronary artery disease. In a recent trial, 27% of patients treated with conventional uncoated stents, but none of the patients treated with sirolimus-eluting stents developed restenosis. 7 Major cardiac events were significantly reduced in the first year following treatment, but this effect was entirely due to a higher revascularization rate in the conventional stent group. Similarly, restenosis and intimal hyperplasia was more effectively reduced by paclitaxel-eluting as compared to conventional stents in another recent randomized trial. 8 However, it is still not known whether routine use of stents rather than balloon angioplasty in non-acute coronary heart disease reduces mortality and other clinical outcomes such as myocardial infarction.
In a meta-analysis of randomized controlled trials, we investigated whether routine use of stents rather than balloon angioplasty reduces mortality and improves clinical outcome in patients with non-acute coronary artery disease.
Methods

Data search and trial selection
We searched Medline, Embase, Pascal, Index medicus, the Cochrane library and abstracts from cardiology conferences from 1979 to March 2002 to identify all randomized controlled trials in non-acute coronary artery disease that compared stents with balloon angioplasty. We used the following search terms: Angioplasty-transluminal-percutaneous-coronary, Stents, Randomized-controlled-trials, Clinical-trials, Coronary-arterydilatation, Transluminal-coronary-angioplasty, Random. In addition, we searched all references of relevant articles for additional trials and if necessary, contacted authors of identified trials to ask for additional information.
Two reviewers independently selected the relevant trials and resolved disagreement by consensus. The same reviewers extracted data from all trials that fulfilled our inclusion criteria.
Inclusion-and exclusion criteria
Trials were included if they met the following criteria: randomization to stents or balloon angioplasty prior to the invasive procedure, intervention in native coronary arteries, reporting death or myocardial infarction, and follow-up of at least 6 months. We excluded trials in patients with acute myocardial infarction where angioplasty was done within 48 h after diagnosis, trials that exclusively randomized patients to provisional stenting and trials where patients were randomized after angioplasty only.
Outcomes
The primary outcome was mortality at 30 days (including in-hospital mortality), and at 6 and 12 months after the intervention. Secondary outcomes were myocardial infarction, coronary artery bypass grafting (CABG), a composite outcome of death and myocardial infarction, target vessel revascularization, and bleeding complications with need of transfusion or surgery.
Assessment of study quality
Two reviewers independently assessed the quality of each included trial according to the following criteria: concealment of treatment allocation, blinded outcome assessment, and full description of follow-up. We summarized the quality rating and used a modified Jadad score (Table 1) . 9 The score gives one point to each of five items (random allocation, blinding, blinded outcome assessment, full description of all losses of follow-up and withdrawals, and loss to follow-up <10%) if present. One additional point is given if randomization is concealed and one if double-blinding is appropriate. Since blinding to stent or balloon angioplasty was not possible, the score could range from 0 to 5 points. Agreement between the two reviewers was assessed by calculating proportions of specific agreement for positive and negative ratings. 10 Disagreement between reviewers was resolved by consensus.
Examination of publication bias
We used a plot of standardized effect against precision to test for the presence of publication bias.
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Data aggregation and sensitivity analysis
We used STATA 7.0 (Stata Corporation, Texas, USA) statistical software to calculate summary risk differences using a fixed effect model. While meta-analyses are often carried out on a relative scale, the risk difference scale is appealing for rare events because of its immediate interpretability and because trials with zero events in both treatment groups can be included in the analysis. 12 In our analysis, the use of summary risk differences was a reasonable approach since there was little difference between trials in event rates in the control group. 13, 14 For easier interpretation, we report differences in event rates per 1000 patients. In addition, we report Peto odds ratios for the primary outcome. Simulation suggests that with rare events, meta-analysis underestimates the true effect of treatment over control, but Peto odds ratios are the least biased and most powerful method of pooling trial results among the methods in common use. 15, 16 When events are at least moderately rare (i.e. one or two per 1000), odds ratios are a close approximation to the relative risk. 12 To explore the stability of the overall treatment effect, we compared the primary outcome in predefined subgroups. 17, 18 These subgroups were: different types of stents, intervention in vessels with large (≥3 mm) and small (<3 mm) diameters, different post-interventional antithrombotic/anticoagulant drug regimens, and use of glycoprotein IIb/IIIa inhibitors. In order to account for an any time-related effect, we performed an additional sensitivity analysis comparing trials starting enrolment of patients before the year 1996 and trials starting enrolment in 1996 or later.
Role of the funding source
The funding source was not involved in study design, collection, analysis, or interpretation of data and had no impact on writing the manuscript or on the decision to submit the paper.
Results
Trials characteristics
Of 602 potentially relevant publications, 24 met our inclusion criteria (Fig. 1) . Five of these publications were long-term follow-up reports of previously published trials 5, [19] [20] [21] [22] and so 19 trials with a total of 8004 patients were included in our meta-analysis (Table 1) . Six different stent types were used in the 19 trials. In 13 trials the target vessel size was ≥3 mm, and in six trials <3 mm. [23] [24] [25] [26] [27] [28] Three trials included only patients with stable coronary artery disease, [29] [30] [31] the remaining trials included patients with stable and unstable angina.
Definitions of acute myocardial infarction varied across trials. Only four trials mentioned pre-specified criteria for the need of target vessel revascularization (Table 2) .
Only three trials used the same postinterventional antithrombotic/anticoagulant therapy in both groups. 6, 30, 32 All other trials used a more aggressive post-interventional therapy in the stent group.
Only two trials used a glycoprotein IIb/IIIa inhibitor (abciximab) as a co-intervention in both treatment arms.
5, 25 The EPISTENT-trial had three treatment arms: we used data from two arms-stents with abciximab and PTCA with abciximab. 5 We did not use data from the third arm (stents with placebo) because there was no comparison group (balloon angioplasty with placebo).
Plots of standardized effects against precision indicated a low probability for the presence of publication bias (P=0.28).
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Agreement on quality rating
Proportions of specific agreement for positive and negative ratings were 0.92 and 0.94 for concealment of treatment allocation, 0 and 0.83 for blinded outcome assessment, and 0.91 and 0.75 for full description of loss of follow-up. Proportions of specific agreement give the probability that one assessment is positive (or negative) given that the other assessment is also positive (or negative). Few trials were thought to have blinded outcome assessment by one reviewer or the other, and reviewers never agreed; hence the positive specific agreement of zero for this item. Both reviewers concluded that all trials lost 10% or fewer patients to follow-up and that all trials had open intervention.
Methodologic quality of trials
Random allocation was concealed in 13 trials and possibly concealed in the other six trials. 5, 27, 30, [32] [33] [34] In all trials, interventions were not blinded for obvious reasons. After consensus, no trial was found to explicitly mention blinded outcome assessment. In all trials, follow-up data were reported for at least 90% of the patients. In all but five trials, a full description of follow-up and withdrawals was given. 4, 26, 31, 34, 35 Clinical outcomes Primary outcome At 30 days, three (95% CI 0 to 6) additional lives were saved per 1000 patients treated with stents rather than balloon angioplasty (Table 3 , Fig. 2 ). Early deaths occurred only in six of 19 trials. For these six trials, the odds ratio for mortality with stents rather than balloon angioplasty was 0.34 (95% CI 0.15-0.81). At 6 months, deaths had occurred in 16 trials. On average 5 (95% CI 0 to 9) additional lives were saved per 1000 patients treated with stents rather than balloon angioplasty. The odds ratio for mortality with stents rather than balloon angioplasty was 0.57 (95% CI 0.34-0.96).
Seven trials reported mortality data at 12 months. 4, 17, 20, 29, 31, 32, 34 Six (95% CI −1 to 12) additional lives were saved per 1000 patients treated with stents rather than balloon angioplasty. The odds ratio for mortality with stents rather than balloon angioplasty was 0.62 (95% CI 0.36-1.05). In each analysis, there was no evidence of heterogeneity (P>0.1).
Secondary outcomes
At 30 days there was no evidence from summary risk differences that stents were superior to balloon angioplasty for myocardial infarction, CABG, target Two of three criteria: prolonged chest pain of cardiac origin not relieved by nitroglycerin, rise in creatine kinase more than twice upper limit of normal, or new pathological Q waves Not prespecified Yes vessel revascularization, and the composite outcome of death and myocardial infarction (Table 3) . At 6 months, 55 (95% CI 40 to 71) target vessel revascularizations were avoided per 1000 patients treated with stents rather than balloon angioplasty. Summary risk differences for myocardial infarction and CABG suggested some benefit from stents over balloon angioplasty, but these differences were not statistically significant.
At 12 months, 46 (95% CI 25 to 66) target vessel revascularizations were avoided per 1000 patients treated with stents rather than balloon angioplasty, and 10 (95% CI 2 to 20) additional deaths or myocardial infarctions were prevented for 1000 patients treated with stents rather than balloon angioplasty. Summary risk differences at 12 months indicated benefit from stenting for all secondary outcomes-with the exception of CABGbut were not statistically significant. In each analysis, there was no evidence of heterogeneity (P>0.1).
Data on post-interventional bleeding complications with need for blood transfusion or surgical intervention were available from 11 trials. The bleeding complication rate ranged from 0 to 21% in patients randomized to stenting, and from 0 to 5% in patients randomized to balloon angioplasty (Table 1) . On average, there were 25 (95% CI 15 to 34) additional bleeding complications per 1000 patients treated with stents rather than balloon angioplasty (test of heterogeneity P>0.1).
Sensitivity analyses
With few early deaths and few trials reporting 12-month mortality, sensitivity analysis for the primary outcome was only appropriate at 6 months. We compared trials using different stent types, trials with interventions in large and small vessels, trials with different post-interventional antithrombotic/anticoagulant drug therapies in both treatment arms and trials routinely using respectively not using glycoprotein IIb/IIIa inhibitors.
The average number of additional lives saved per 1000 patients treated with stents rather than PTCA was: five (95% CI 0 to 10) in trials using Palmaz-Schatz stents and four (95% −5 to 10) in trials using other stents; five (95% CI 0 to 10) in trials with intervention in large vessels and five (95% CI −5 to 20) in trials with intervention in smaller vessels; six (95% CI 0 to 10) in trials with more aggressive post-interventional antithrombotic/anticoagulant drug therapies in the stent group and one (95% CI −7 to 9) in those three trials with identical post-interventional therapies in both groups; 5, 28, 30 ; 11 (95% CI 2 to 20) in those two trials 5, 25 routinely using a glycoprotein IIb/IIIa inhibitor in both treatment groups and two (95% CI −4 to 7) in all other trials not routinely using a glycoprotein IIb/IIIa inhibitor; −1 (95% CI −9 to 7) in trials starting patient enrolment before 1996 and seven (95% CI 1 to 13) in trials starting patient enrolment in 1996 or later (test of heterogeneity for all comparisons P>0.1).
In order to differentiate between the effects of timerelated improvements in stenting technique and the use of a glycoprotein IIb/IIIa inhibitors, we repeated our analysis of trials enrolling patients from 1996 and later after exclusion of those two trials routinely using glycoprotein IIb/IIIa inhibitors. By doing so, the average number of additional lives saved per 1000 patients treated with stents rather than PTCA was four (95% CI −3 to 11).
Discussion
Our meta-analysis shows that routine use of stents rather than balloon angioplasty reduces overall mortality at 6 months in patients with non-acute coronary artery disease. This benefit, however, is small and corresponds to five (95% CI 0 to 9) additional saved lives per 1000 patients treated. The benefit seems to persist at 12 months with six (95% CI −1 to 12) additional saved lives per 1000 patients. At 12 months, patients treated with stents rather than balloon angioplasty required between 25 and 66 fewer target vessels revascularizations per 1000 patients treated. This benefit, however, is tempered by a higher risk of post-interventional bleedings (15 to 34 additional bleedings per 1000 patients treated with stents rather than balloon angioplasty).
The evidence that stents reduce mortality is weaker when measured with risk differences than when measured with odds ratios. Simulation suggests that both measures will underestimate the true effect of stents rather than balloon angioplasty. 15 While Peto odds ratios may be less biased than risk differences when events are rare, the implications of excluding trials with no events in both groups has never been fully investigated. 12 Using risk differences, which include such trials, is therefore a conservative approach.
Following a comprehensive literature search, we included additional unpublished data from individual trials by contacting authors of published trials to provide information not readily available form the published trials and of one trial that had been published only in abstract form. 26 We have no evidence of a publication bias, although such a bias is always possible. We explored heterogeneity between trials according to a priori defined criteria but found no evidence for heterogeneity. A lack of power could be a reason for our failure to detect heterogeneity. The usual test for heterogeneity has low power, 37 particularly in meta-analyses of rare events. 12 However, various clinical trials comparing different stent types have not shown any difference on clinical outcomes such as mortality and reinfarction rates. [38] [39] [40] [41] [42] [43] [44] There may be a higher risk of restenosis and revascularization with the Gianturco-Roubin flex stent, 45 but this stent was not used in any of the trials in our analysis.
Given that stents seem to be associated with a lower mortality than balloon angioplasty, we would have expected a lower rate of myocardial infarction in patients treated with stents. Possibly, stents reduce acute plaque rupture of high-risk lesions and so reduce sudden death, but have less effect on non-fatal myocardial infarction. Unfortunately, we do not have the necessary data on sudden death to test this hypothesis.
This meta-analysis has some limitations. Cross-over rates from balloon angioplasty to stents in the included trials were substantial and ranged from 0 to 57% (Table  1) . Thus, we may underestimate the true effects of stents. None of the included trials were found to report blinded outcome assessment. While blinded outcome assessment is irrelevant for mortality, the primary endpoint of our study, its absence limits the reliability of results for the secondary outcomes.
Pre-specified comparisons for relevant subgroup analysis of stent types and vessel size remained inconclusive due to lack of power. Only three trials used the same post-interventional antithrombotic/anticoagulant therapy in both groups. 6, 30, 32 All other trials used a more aggressive post-interventional therapy in the stent group. Our sensitivity analysis lacked power to detect what could be a clinically significant difference in mortality between trials with balanced and unbalanced cointervention. Therefore, we can not be sure that the reduced mortality in patients treated with stents is really due to stenting and not to unbalanced co-intervention.
The beneficial effect of stenting on mortality was only seen in trials that started patient enrolment in 1996 or later. This implies that advances in stenting technique over the past few years may account for the reduction in mortality. However, the concomitant use of glycoprotein IIb/IIIa inhibitors seems to be the most important factor responsible for the observed benefit of stenting on mortality as demonstrated by our sensitivity analysis. Even modern stenting techniques do not seem to reduce mortality in comparison to balloon angioplasty in the absence of concomitant use of a glycoprotein IIb/IIIa inhibitor. Importantly, the concomitant use of glycoprotein IIb/IIIa inhibitors does not seem to be associated with a higher risk of bleeding complications. In the Epistent trial 5 major bleeding episodes were not higher in patients treated with stents or balloon angioplasty plus abciximab than in patients treated with stents plus placebo. The generally higher bleeding risk associated with stenting observed in this meta-analysis may be due to inclusion of earlier trials that used more aggressive anticoagulant therapy. Recently, high levels of procedural anticoagulation with heparin were found to increase haemorrhagic complications without improving clinical outcome in cardiac patients treated with stents. 46 Based on these results, activated clotting times within a range of 150 to 275 s seem to be associated with the lowest risk of bleeding complications.
The external validity of our findings may be limited. Many trials were conducted in specialized high volume centres and some of them included highly pre-selected patients. Therefore, our results may not necessarily apply to patients treated in other centres or settings. We were not able to get individual patient data and therefore unable to evaluate the effects of stenting in important subgroups such as women, diabetic and elderly patients. Women, diabetic and elderly patients were clearly under-represented in the trials included into our meta-analysis. More data on the effects of stenting in these patients are required, especially in the elderly, since angioplasty is increasingly used in older patients with severe angina because it is less invasive than bypass surgery.
We excluded trials that exclusively randomized patients to provisional stenting, a technique that may be less effective, but also less costly than routine stenting. 47 Finally, the trials included into our meta-analysis were of relatively short duration and there is a clear need for more data on the long-term benefits of stents in coronary angioplasty. Cohort studies and national or regional registries could be used to collect this important information.
A recent meta-analysis comparing routine coronary stenting to balloon angioplasty concluded that stenting is safe but probably not associated with important reductions in rates of mortality and acute myocardial infarction. 48 However, this meta-analysis also included trials that randomized patients to stents only after balloon angioplasty had already been performed successfully. This may lead to an underestimation of the true effects of stenting since only patients with optimal balloon angioplasty results served as controls. Furthermore, the beneficial effect of the conjunctive use of glycoprotein IIb/IIIa inhibitors to stents was missed, because no evaluation of the impact of different antithrombotic cointerventions was performed in that study. Another recent meta-analysis that included data derived from stent registries failed to demonstrate any difference in mortality and infarction rates between patients treated by stenting and balloon angioplasty. 49 Inadequate power due to insufficient sample size and lack of inclusion of trials using glycoprotein IIb/IIIa inhibitors may explain why no significant differences were observed in that meta-analysis.
A meta-analysis comparing stents to balloon angioplasty in patients with acute myocardial infarction and with similar follow-up times failed to show any statistically significant difference in mortality (OR 1.04, 95% CI 0.75 to 1.44 for stents versus balloon angioplasty). 50 This could be due to the higher baseline risk of procedure-and non-procedure-related mortality in acute compared to non-acute coronary artery disease.
Stent technology has developed considerably over the last few years. There is now a broad variety of stents with different physical and antithrombotic properties. Clinical trials are needed comparing different stent types or stents with and without new co-interventions such as drug-eluting stents or endoluminal beta-emitting radiation therapy. 7, 8, 51 Trials with longer follow-up are needed comparing stents with other promising revascularization procedures such as minimally invasive bypass surgery. 52 Some cost-effectiveness studies have clearly favoured stents over balloon angioplasty 53 while others have been inconclusive. 54, 55 It is clear that stents will become more economically attractive as their in-hospital costs decrease. New stent types are likely to be associated with higher in-hospital cost and so costeffectiveness analyses will be needed to justify their use.
In conclusion, routine use of stents rather than balloon angioplasty in the treatment of non-acute coronary artery disease is associated with a reduced risk of both mortality and revascularization up to 6 months of followup. The benefit on mortality seems to be limited to stenting with concomitant use of glycoprotein IIb/IIIa inhibitors. These benefits outweigh a higher risk of postinterventional bleeding complications in patients treated with stents.
